文献速递血栓与止血

应用液相酶免疫分析法研究4种抗PF4疾病中抗PF4与抗PF4/肝素的反应性:经典肝素诱导的血小板减少症、自身免疫性肝素诱导的血小板减少症、疫苗诱导的免疫性血栓性血小板减少症及自发性肝素诱导的血小板减少症

Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT.
PubMed 文献 · J Thromb Haemost · 2023-05-12

研究开发液相酶免疫分析法(fluid-EIA)比较4种抗PF4疾病中抗PF4与抗PF4/肝素抗体谱。结果:经典HIT血清27份中27份(100%)与PF4/肝素反应阳性,仅4份(14.8%)与PF4单独反应阳性;VITT血清17份中17份(100%)与PF4单独反应阳性,与PF4/肝素结合明显降低;所有自身免疫性HIT和自发性HIT血清均与PF4单独反应阳性,但与PF4/肝素反应可变。

要点

  • 经典HIT血清液相EIA显示PF4/肝素结合强于PF4单独结合,多数对PF4单独阴性。
  • VITT血清液相EIA显示PF4单独结合强于PF4/肝素结合,该特征固相EIA未能显示。
  • 所有自身免疫性HIT和自发性HIT血清均与PF4单独反应阳性,与PF4/肝素反应可变。

核心结论

  • 经典HIT与VITT血清呈现相反的液相EIA特征:经典HIT为PF4/肝素>>PF4(多数对PF4单独阴性),VITT为PF4>>PF4/肝素(多数对PF4/肝素阴性)。
  • 所有自身免疫性HIT和自发性HIT血清均与PF4单独反应,但与PF4/肝素反应可变(通常增强)。
  • 仅少数自发性HIT和自身免疫性HIT患者出现模拟VITT的临床/血清学特征。

研究设计与样本

  • 研究开发了新型液相酶免疫分析法(fluid-EIA)以检测抗PF4与抗PF4/肝素抗体。
  • 比较了经典HIT、自身免疫性HIT、自发性HIT和VITT血清在固相和液相EIA中的抗体谱。

主要发现

  • 经典HIT血清27份中27份(100%)液相EIA检测IgG与PF4/肝素阳性,仅4份(14.8%)与PF4单独阳性;全部27份显示肝素增强结合。
  • VITT血清17份中17份(100%)液相EIA检测IgG与PF4单独阳性,与PF4/肝素结合明显降低;该特征固相EIA未显现。
  • 自身免疫性HIT血清15份全部与PF4单独阳性,其中14份(14/15)显示肝素增强结合;自发性HIT血清11份全部与PF4单独阳性,其中10份(10/11)显示肝素增强结合。
  • 1例自发性HIT患者液相EIA特征模拟VITT(PF4>>PF4/肝素),临床也类似VITT(病毒感染后脑静脉/窦血栓形成),抗PF4反应性与血小板计数恢复呈负相关;1例自身免疫性HIT患者液相EIA特征模拟VITT,也发生病毒感染后脑静脉/窦血栓形成。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Four platelet-activating anti-platelet factor 4 (PF4) disorders have been recognized: classic heparin-induced thrombocytopenia (cHIT), autoimmune heparin-induced thrombocytopenia (aHIT), spontaneous heparin-induced thrombocytopenia (SpHIT), and vaccine-induced immune thrombotic thrombocytopenia (VITT). All test immunoglobulin G (IgG) positive using solid-phase enzyme immunoassay (solid-EIA) against PF4/heparin (PF4/H) and/or PF4 alone. Fluid-phase EIA (fluid-EIA) should better discriminate between anti-PF4 and anti-PF4/H antibodies since conformationally altered PF4 bound to solid phase is avoided. OBJECTIVES: To compare anti-PF4 vs anti-PF4/H antibody profiles for anti-PF4 disorders using solid- and fluid-EIA. METHODS: We developed a novel fluid-EIA to measure anti-PF4 vs anti-PF4/H antibodies. RESULTS: Using fluid-EIA, 27 of 27 (100%) cHIT sera tested IgG positive with PF4/H, but only 4 of 27 (14.8%) tested positive against PF4 alone; all 27 exhibited heparin-enhanced binding. In contrast, 17 of 17 (100%) VITT sera tested IgG positive against PF4 alone, with markedly reduced binding against PF4/H; this distinct VITT antibody profile was not evident using solid-EIA. All 15 aHIT sera and all 11 SpHIT sera tested IgG positive against PF4 alone, with variable reactivity in PF4/H-EIA (heparin-enhanced binding in 14 of 15 and 10 of 11 aHIT and SpHIT sera, respectively). Remarkably, 1 SpHIT patient with a VITT-mimicking fluid-EIA profile (PF4 >> PF4/H) also clinically resembled patients with VITT (postviral cerebral vein/sinus thrombosis), with anti-PF4 reactivity correlating inversely with platelet count recovery; moreover, the single aHIT patient with a VITT-mimicking fluid-EIA profile also developed postviral cerebral vein/sinus thrombosis. CONCLUSION: cHIT and VITT sera showed opposite fluid-EIA profiles (cHIT: PF4/H >> PF4, with most testing negative against PF4 alone; VITT: PF4 >> PF4/H, with most testing negative against PF4/H). In contrast, all aHIT and SpHIT sera reacted against PF4 alone but with variable (usually enhanced) reactivity against PF4/H. VITT-mimicking clinical/serologic profiles occurred in only a minority of patients with SpHIT and aHIT.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Warkentin TE, Arnold DM, Sheppard JI, et al. Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT. J Thromb Haemost. 2023. PMID: 37182698. doi:10.1016/j.jtha.2023.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。